Syngene, a World-leading Contract Research Organization, Chooses Reaxys® to Enhance Productivity and Competitiveness
Frankfurt, Germany - 13 May 2011 – Elsevier, the world’s leading publisher of scientific content and online solutions announced today that Syngene, India’s first contract research organization, has signed a multi-year contract that will provide unlimited access to Reaxys for all Syngene researchers. Reaxys will help Syngene enhance its R&D competitiveness and productivity in the ever-expanding and highly competitive Indian pharmaceutical, chemical and agrochemical research environments.
Dr. Manoj Nerurkar, Head of Small Molecule Discovery & Development at Syngene, said of the agreement, “It’s critical for our scientists to have immediate access to the relevant chemical information. We have to generate maximum output with a minimum number of experiments. The insights Reaxys gives us into possible synthetic routes and validated physical property data is crucial in ensuring that when we start in the lab we will generate better output in less time. Starting with Reaxys, we can be sure that the information is reliable and we will not be led down any false routes.”
Syngene is already a preferred research service provider to leading players in global pharmaceutical and chemical industries who continue to invest and commit to enlarging their R&D activities in India. Access to Reaxys’ validated, curated chemical information will be a key factor in helping Syngene maintain this position.
“Reaxys is dedicated to providing the relevant information that will enable researchers to innovate effectively: to act immediately on their findings from Reaxys and apply them directly in the lab,” said Mark van Mierle, Managing Director, Pharma and Biotech Group, Elsevier. “We are pleased to extend our relationship with Syngene and we look forward to continuing to support it in its ongoing R&D efforts.”
# # #
Established in 1994, Biocon subsidiary Syngene is an internationally reputed contract research and manufacturing organisation with multidisciplinary skills in chemistry, biology, process development and scale-up, formulation and analytical development and preclinical services. India’s first Contract Research Organization (CRO), it has successfully partnered with leading players in global pharmaceutical, biotechnology, chemical and agrochemical industries across a wide range of discovery and development programmes.
From early stage discovery and process development through to cGMP manufacturing, it provides customised services to pharmaceutical and biotechnology majors on a strong platform of confidentiality and intellectual property protection. Its deep scientific talent pool and state-of-the-art R&D and production facilities enable it to enhance productivity and accelerate delivery of all projects with the highest degree of professionalism.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact
Vice President, Global Corporate Relations